drugset / Trial / NCT04227093

Acetazolamide Add-On Therapy to OSA Surgery

NCT04227093

Phase 4 Unknown 26 enrolled University Hospital, Antwerp
RandomizedParallel-groupDouble-blindTreatment

Summary

Surgical procedures are routinely performed as an alternative to continuous positive airway pressure treatment in patients with obstructive sleep apnea (OSA). However, the response to surgery is often variable. Instability of the respiratory control during sleep (or high loop gain) has been associated with poor surgical results in previous research. Acetazolamide (AZM), a carbonic anhydrase inhibitor, has shown potential in reducing loop gain without affecting other physiological OSA traits. In this protocol the investigators will evaluate the clinical efficacy of AZM add-on therapy to surgical procedures in patients with OSA.

Timeline

Start
2020-01-22
Primary completion
2023-04-22
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetazolamide Small molecule 250 mg Oral